Legend Biotech (LEGN) Other Non-Current Liabilities (2020 - 2025)
Legend Biotech (LEGN) reported Other Non-Current Liabilities of $8.0 million for Q4 2025, up 31.15% on a YoY basis from $6.1 million in Q4 2024, and down 1.54% quarter-over-quarter from $8.1 million in Q3 2025.
Legend Biotech (LEGN) Other Non-Current Liabilities (2020 - 2025) Analysis & Trends
Legend Biotech has reported Other Non-Current Liabilities for 6 years, with the latest figure at $8.0 million in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities rose 31.15% year-over-year to $8.0 million; the trailing twelve-month figure through Dec 2025 stood at $8.0 million (up 31.15% YoY), and the FY2025 full-year result was $8.0 million, up 31.15% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $8.0 million, down from $8.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $8.1 million in Q3 2025, with the low at $554.0 in Q1 2021.
- Historically, Other Non-Current Liabilities has averaged $1.7 million across 5 years, with a median of $224000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 64159.93% — and 2024, when it sank 86.61%.
- Legend Biotech's Other Non-Current Liabilities stood at $396000.0 in 2021, then sank by 41.16% to $233000.0 in 2022, then tumbled by 75.97% to $56000.0 in 2023, then soared by 10792.86% to $6.1 million in 2024, then surged by 31.15% to $8.0 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $8.0 million (Q4 2025), $8.1 million (Q3 2025), and $6.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.00 Mn |
| Sep 30, 2025 | 8.13 Mn |
| Dec 31, 2024 | 6.10 Mn |
| Sep 30, 2024 | 27,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 56,000.00 |
| Sep 30, 2023 | 119,000.00 |
| Jun 30, 2023 | 152,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Dec 31, 2022 | 233,000.00 |
| Mar 31, 2022 | 356,000.00 |
| Dec 31, 2021 | 396,000.00 |
| Sep 30, 2021 | 991,000.00 |
| Jun 30, 2021 | 554.00 |
| Mar 31, 2021 | 554.00 |
| Dec 31, 2020 | 554,000.00 |